CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 121 enrolled
Drug / intervention
PF-07242813 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04668066
NCT04668066Phase 1Completed
CompareCT.gov

A PHASE 1 FIRST IN HUMAN, RANDOMIZED, DOUBLE BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF 07242813 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ATOPIC DERMATITIS

Pfizer·interventional·Posted Dec 16, 2020·Updated Jun 3, 2024

In Brief

A Phase 1 clinical trial evaluating PF-07242813 and Placebo for Atopic Dermatitis. Completed, enrolled 121 participants across 7 sites.

Detailed Summary

This is the first time PF-07242813 will be given to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07242813 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07242813 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedDec 16, 2020
Enrollment StartDec 10, 2020
Primary CompletionDec 27, 2022
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 5.5 years ago

Interventions

PF-07242813drug

PF-07242813 given intravenously or subcutaneous

Placebodrug

Placebo given intravenously or subcutaneous